462 related articles for article (PubMed ID: 19681863)
1. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments.
Seneschal J; Milpied B; Vergier B; Lepreux S; Schaeverbeke T; Taïeb A
Br J Dermatol; 2009 Nov; 161(5):1081-8. PubMed ID: 19681863
[TBL] [Abstract][Full Text] [Related]
2. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies.
Laga AC; Vleugels RA; Qureshi AA; Velazquez EF
Am J Dermatopathol; 2010 Aug; 32(6):568-73. PubMed ID: 20520526
[TBL] [Abstract][Full Text] [Related]
3. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists.
Asarch A; Gottlieb AB; Lee J; Masterpol KS; Scheinman PL; Stadecker MJ; Massarotti EM; Bush ML
J Am Acad Dermatol; 2009 Jul; 61(1):104-11. PubMed ID: 19539844
[TBL] [Abstract][Full Text] [Related]
4. CXCR3 <-> ligand-mediated skin inflammation in cutaneous lichenoid graft-versus-host disease.
Wenzel J; Lucas S; Zahn S; Mikus S; Metze D; Ständer S; von Stebut E; Hillen U; Bieber T; Tüting T
J Am Acad Dermatol; 2008 Mar; 58(3):437-42. PubMed ID: 18280341
[TBL] [Abstract][Full Text] [Related]
5. Type I interferon-associated cytotoxic inflammation in lichen planus.
Wenzel J; Scheler M; Proelss J; Bieber T; Tüting T
J Cutan Pathol; 2006 Oct; 33(10):672-8. PubMed ID: 17026519
[TBL] [Abstract][Full Text] [Related]
6. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis.
Wenzel J; Schmidt R; Proelss J; Zahn S; Bieber T; Tüting T
Clin Exp Dermatol; 2006 Jul; 31(4):576-82. PubMed ID: 16716166
[TBL] [Abstract][Full Text] [Related]
7. Psoriasiform reactions to anti-tumor necrosis factor α therapy.
Nguyen K; Vleugels RA; Velez NF; Merola JF; Qureshi AA
J Clin Rheumatol; 2013 Oct; 19(7):377-81. PubMed ID: 24048106
[TBL] [Abstract][Full Text] [Related]
8. CXCR3-mediated recruitment of cytotoxic lymphocytes in lupus erythematosus profundus.
Wenzel J; Proelss J; Wiechert A; Zahn S; Bieber T; Tüting T
J Am Acad Dermatol; 2007 Apr; 56(4):648-50. PubMed ID: 17367614
[TBL] [Abstract][Full Text] [Related]
9. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus.
Wenzel J; Wörenkämper E; Freutel S; Henze S; Haller O; Bieber T; Tüting T
J Pathol; 2005 Mar; 205(4):435-42. PubMed ID: 15685590
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview.
Pirard D; Arco D; Debrouckere V; Heenen M
Dermatology; 2006; 213(3):182-6. PubMed ID: 17033165
[TBL] [Abstract][Full Text] [Related]
11. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha?
Cuchacovich R; Espinoza CG; Virk Z; Espinoza LR
J Clin Rheumatol; 2008 Dec; 14(6):353-6. PubMed ID: 19033869
[TBL] [Abstract][Full Text] [Related]
12. Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in psoriasis.
Campanati A; Orciani M; Gorbi S; Regoli F; Di Primio R; Offidani A
Br J Dermatol; 2012 Jul; 167(1):68-76. PubMed ID: 22356229
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte colony-stimulating-factor-induced psoriasiform dermatitis resembles psoriasis with regard to abnormal cytokine expression and epidermal activation.
Mössner R; Beckmann I; Hallermann C; Neumann C; Reich K
Exp Dermatol; 2004 Jun; 13(6):340-6. PubMed ID: 15186319
[TBL] [Abstract][Full Text] [Related]
14. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
[TBL] [Abstract][Full Text] [Related]
16. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
[TBL] [Abstract][Full Text] [Related]
17. Psoriasiform and pustular eruption induced by infliximab.
Takahashi H; Hashimoto Y; Ishida-Yamamoto A; Ashida T; Kohgo Y; Iizuka H
J Dermatol; 2007 Jul; 34(7):468-72. PubMed ID: 17584325
[TBL] [Abstract][Full Text] [Related]
18. The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets.
Wenzel J; Zahn S; Mikus S; Wiechert A; Bieber T; Tüting T
Br J Dermatol; 2007 Oct; 157(4):752-7. PubMed ID: 17714558
[TBL] [Abstract][Full Text] [Related]
19. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.
Sfikakis PP; Iliopoulos A; Elezoglou A; Kittas C; Stratigos A
Arthritis Rheum; 2005 Aug; 52(8):2513-8. PubMed ID: 16052599
[TBL] [Abstract][Full Text] [Related]
20. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists.
Hawryluk EB; Linskey KR; Duncan LM; Nazarian RM
J Cutan Pathol; 2012 May; 39(5):481-92. PubMed ID: 22515220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
